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Abstract
Background: Egypt is the nation most affected by hepatitis C virus (HCV) infection, fol-
lowing an epidemic of historic proportions. We aimed to characterize the epidemic’s his-
torical evolution and to delineate the role of parenteral antischistosomal therapy (PAT)
campaigns in transmission.
Methods: A mathematical model was constructed and analysed in order to understand
HCV-transmission dynamics. The model was fitted to Egypt’s Demographic and Health
Survey data and to a systematic database of HCV-prevalence data.
Results: The incidence rate peaked in 1966 at 15.7 infections per 1000 person-years—a
period of time that coincides with the PAT campaigns—and rapidly declined thereafter,
beginning the mid-1990s. The annual number of new infections peaked in 1993 at
581 200 (with rapid demographic growth), leading to a high-incidence-cohort effect, and
declined to 67 800 by 2018. The number of individuals ever infected (1950–2018) was
16.4 million, with HCV prevalence peaking in 1979. The number of individuals ever ex-
posed to PAT was 8.3 million; however, of these individuals, 7.3 million were alive in
1980 and only 3.5 million alive in 2018. The number of individuals ever infected due to
PAT exposure was 963 900, with 850 200 individuals alive in 1980 and only 389 800 alive
in 2018. The proportion of PAT-attributed prevalent infections peaked at 19.9% in 1972,
declining to 5.5% by 2018.
Conclusions: PAT campaigns played an important role in HCV transmission, yet explain
only 6% of infections—they appear to be a manifestation, rather than a cause, of the epi-
demic. A possible driver of the epidemic could be the mass expansion of inadequate-
quality healthcare during PAT campaigns and subsequent decades. Despite a historic
toll, the epidemic has been rapidly diminishing since the mid-1990s.
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Introduction
Viral hepatitis is the seventh leading cause of mortality, ex-
ceeding that of HIV, tuberculosis and malaria.1 Half of all
viral hepatitis-related deaths are caused by hepatitis C vi-
rus (HCV) infection,1 whose sequelae include hepatitis, fi-
brosis, cirrhosis and liver cancer.1–3 HCV antibody (Ab)
prevalence is estimated to be 1% for the global popula-
tion,4 in stark contrast to Egypt, which is estimated to
have a prevalence of 10%5–8—possibly the highest preva-
lence worldwide.8–10
The era of mass campaigns of parenteral antischistoso-
mal therapy (PAT) is believed to be the main driver of this
epidemic.5,11 Millions of people received intravenous injec-
tions of tartar emetic as treatment for schistosomiasis be-
tween the 1950s and early 1980s, particularly in rural
areas.5,7,8 An oral drug, praziquantel, was subsequently in-
troduced in the 1980s, replacing the standard of care.5
Based on indirect evidence and risk-factor analyses of mul-
tiple cross-sectional surveys,5,6,8,11–33 it is believed that re-
use of glass syringes and lax infection-control practices
during these campaigns created a large reservoir of HCV
infection in the population.5,8,10,34 Whereas the current in-
fection levels in Egypt are well characterized with quality
data,5–9,35–37 the historical role of PAT in the epidemic
remains poorly characterized.6–8
Against this background, we aimed to provide a de-
tailed quantitative assessment of the historical role of PAT
exposure in HCV transmission in Egypt. In addition to es-
timating the proportion of incident and prevalent infec-
tions strictly attributed to PAT exposure, we estimated the
past levels and trends of HCV Ab prevalence, incidence
rate, annual number of new infections, PAT exposure and
HCV Ab prevalence among those who were exposed to
PAT. Accordingly, we provided a comprehensive charac-
terization of the world’s most distinguished HCV epidemic
and delineated the role of PAT campaigns in this epidemic.
A major strength of this study is that it is anchored on
nationally representative and population-based HCV and
PAT-exposure data, and an exhaustive database of HCV
Ab-prevalence data. This study used prevalence measures
recently extracted through a systematic review of HCV in-
fection in Egypt.6 The present study also accounted for the
intricate and rapidly evolving demography of the Egyptian
population over the past few decades.
Methods
Mathematical model
A dynamical mathematical model was constructed by
extending and adapting earlier models9,38 to describe HCV
transmission in the population of Egypt. The model explic-
itly incorporated HCV acquisition through PAT exposure.
The population that has not been exposed to PAT could
acquire HCV infection only through modes of exposure
other than PAT exposure. Meanwhile, the population that
has been exposed to PAT could acquire HCV infection ei-
ther through PAT exposure or through other modes of ex-
posure (model equations in the Supplementary data are
available at IJE online). A descriptive diagram of the
model is shown in Supplementary Figure 1, available as
Supplementary data at IJE online.
The model structured the population by age group,
status of infection, stage of infection and infection risk of
exposure. Infection natural history consisted of three
stages including primary acute infection, secondary acute
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infection and chronic infection.9,38,39 Egypt’s population
was disaggregated into 13 age groups based on available
HCV Ab-prevalence data: 0–4, 5–9, 10–14, 15–19, 20–24,
25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59 and
>60 years old.
To represent the variability in the infection risk of expo-
sure, five risk groups (other than PAT exposure) were
modelled in the population. The mixing between the vari-
ous risk groups and age groups was dictated by mixing ma-
trices. The force of infection was determined by the
iatrogenic contact rate, infection-transmission probability
per contact, risk-group mixing and age-group mixing.
HCV treatment scale-up was not incorporated in the
model, as the modelling was focused on the historical evo-
lution of the epidemic before treatment onset. The impact
of HCV treatment on the epidemic in Egypt has already
been assessed in our previous study.9
A detailed description of the model is shown in
Supplementary Section 1, available as Supplementary data
at IJE online. Further details on this type of modelling ap-
proach can be found in earlier publications.9,38
Epidemiologic measures
Different epidemiologic measures were used to describe the
epidemic and its trends, with a focus on the role of PAT ex-
posure in the epidemic. These measures are listed in
Table 1 along with their definitions.
Data sources and model fitting
Current data for HCV transmission and natural history
were used to parameterize the model (Supplementary
Table 1, available as Supplementary data at IJE online).
Historical demographics (1950–2018) were extracted from
the United Nations Population Division database.40 HCV
and PAT-exposure input epidemiological data were esti-
mated from the 2008 and 2015 Egypt Demographic and
Health Surveys (EDHS).10,34 These data include the age-
specific HCV Ab prevalence, population proportion of
PAT exposure, HCV Ab prevalence among those exposed
to PAT and the proportion of individuals exposed to PAT
among those who were HCV Ab-positive.
The time series of HCV Ab prevalence was generated
using 259 systematically extracted Ab-prevalence data
points obtained through a systematic review of HCV infec-
tion in Egypt.6 These data were measured on different pop-
ulations over 1990–2016, with the populations categorized
as general populations, populations at intermediate risk,
high-risk clinical populations, special clinical populations
and populations with liver-related conditions.6
The prevalence measures (in those other than the gen-
eral population) may not be representative of the general
population and thus were used to determine only the HCV
Ab-prevalence trend (not prevalence level). Specifically,
these measures were converted into a corresponding preva-
lence trend by multiplying each measure in each specific
population category by a factor (labelled as the ‘anchoring
factor’). The temporal variation of HCV Ab prevalence in
the population was determined by fitting the anchored
prevalence datapoints over 1990–2016, thereby determin-
ing the anchoring factors, as well as fitting the 2008 and
2015 EDHS data10,34 (Supplementary Figure 5, available
as Supplementary data at IJE online). The fitting of the
EDHS data was set at 100% relative weight, since these
are the best-quality nationally representative probability-
based data in Egypt, whereas the fitting to the anchored
prevalence datapoints was set at 10% relative weight.
Table 1. Epidemiologic measures used to characterize the HCV epidemic and its trends, with a focus on the role of PAT exposure
in the HCV epidemic of Egypt
Measure Definition
HCV antibody (Ab) prevalence Proportion of a given population who are positive for HCV Ab, i.e. proportion of
the population who have ever been infected with HCV
Annual number of new HCV infections (also known
as HCV incidence)
Number of new HCV infections in a given population over the duration of a year
HCV-incidence rate (also known as force of infec-
tion or hazard rate of infection)
Number of new HCV infections per person-time of the at-risk population, i.e. HCV
incidence divided by the population size of the at-risk susceptible population
Population proportion of PAT exposure Proportion of the population who have ever been exposed to PAT
Proportion of prevalent infections strictly attributed
to PAT
Number of living individuals who have ever been infected by HCV due to PAT ex-
posure divided by the total number of living individuals who have ever been
infected by HCV regardless of the mode of transmission
Proportion of new HCV infections strictly attributed
to PAT
HCV incidence due to PAT exposure divided by the total HCV incidence regardless
of the mode of transmission
HCV, hepatitis C virus; PAT, parenteral antischistosomal therapy; Ab, antibody.
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The model was fitted to data by utilizing a generalized
Lognormal-Gaussian function for the effective rate of in-
fectious contacts (Supplementary Figure 2, available as
Supplementary data at IJE online) and using a nonlinear
least-square fitting method implemented in MATLABV
R 41
using the Nelder–Mead simplex algorithm.42 The formula
for the rate of exposure to PAT can be found in
Supplementary Section 1, available as Supplementary data
at IJE online.
Further details on data sources and model fitting are
shown in Supplementary Section 2, available as
Supplementary data at IJE online.
Uncertainty analysis and sensitivity analyses
A multivariable uncertainty analysis was implemented to
derive the uncertainty ranges of the predicted outcomes. A
total of 1000 runs of the model were conducted utilizing
Latin Hypercube sampling from a multidimensional distri-
bution of the model’s structural parameters, with 25% un-
certainty around each parameter point estimate. The
means and associated 95% uncertainty intervals (UIs) were
reported for the key indicators that characterize the role of
PAT exposure in the HCV epidemic. Further details on the
uncertainty analysis are shown in Supplementary Section
2, available as Supplementary data at IJE online.
We conducted a sensitivity analysis to assess the impact
of under-reporting or over-reporting of PAT exposure by
adjusting the self-reported PAT-exposure data by 650%.
We also conducted a sensitivity analysis to assess the im-
pact of HCV disease-related mortality on the model predic-
tions. This was done by incorporating the relative risk of
HCV disease-related mortality stratified by age in the
model based on the mortality data of a prospective study
from Egypt.43
Results
The model generated robust fits to the various data sour-
ces. Supplementary Figure 3, available as Supplementary
data at IJE online, shows the fit to Egypt’s demographics.
Supplementary Figure 4, available as Supplementary data
at IJE online, shows the fit to the different HCV and PAT-
exposure indicators as extracted from the 2008 and 2015
EDHS data.10,34 Supplementary Figure 5, available as
Supplementary data at IJE online, shows the anchored fit
to the HCV Ab-prevalence data of the systematic review.6
Figure 1 reports model predictions for the trend in HCV
Ab prevalence in the total population of Egypt including
all age groups (Figure 1A) and trends in prevalence in chil-
dren (0–14 years), adults (15–59 years) and older adults
(>60 years) (Figure 1B). HCV prevalence was rising for
several decades and reached its peak in 1979, but was pro-
jected to decline slowly thereafter. HCV prevalence by age
group was similar to that in the total population, but the
peak shifted to later years for the older age groups. The
earliest peak was in 1970 for children and the latest in
1991 for older adults.
The HCV-incidence rate in the total population and the
annual number of new HCV infections (HCV incidence)
can be seen in Figure 2A and B, respectively. The incidence
rate peaked in 1966 at 15.7 infections per 1000 person-
years and rapidly declined thereafter, starting in mid-
1990. The incidence was estimated at 8.0 per 1000
person-years in 2000, but at only 0.7 per 1000 person-
years in 2018. Meanwhile, with the rapid demographic
growth in Egypt (Supplementary Figure 3, available as
Supplementary data at IJE online), the annual number of
new infections peaked much later in 1993 at 581 200 and
declined thereafter down to 491 200 in 2000 and 67 800
in 2018. The cumulative number of individuals who have
ever been infected by HCV since 1950 was 16.4 million by
2018, but the number of these individuals alive in 1980
was 4.7 million, 8.6 million in 2000 and 7.1 million in
2018 (Table 2).
Table 2 and Figures 3 and 4 report key indicators that
characterize the historical role of PAT exposure in HCV
transmission. The population proportion of PAT exposure
was increasing with the mass campaigns and estimated at
0.2% in 1950, 5.1% in 1960 and 17.2% in 1970
(Figure 3A). It reached a peak of 18.8% in 1974 and de-
clined thereafter to 8.5% by 2000 and 3.8% by 2018
(Figure 3A). The cumulative number of individuals who
have ever been exposed to PAT was 8.3 million by 2018,
but the number of them who were alive was 7.3 million in
1980, 5.6 million in 2000 and only 3.5 million in 2018
(Table 2).
HCV Ab prevalence in those exposed to PAT peaked in
2008 at 42.4% and declined slowly thereafter to 40.6% in
2018 (Figure 3B). The number of HCV-prevalent infec-
tions (regardless of whether attributed to PAT or not)
among those who have ever been exposed to PAT and alive
was estimated at 1.9 million in 1980, 2.3 million in 2000
and 1.5 million in 2018 (Table 2). The proportion of indi-
viduals exposed to PAT among the total HCV Ab-positive
population was growing and reached a peak of 35.5% in
1977, but declined thereafter to 26.5% by 2000 and
21.0% by 2018 (Figure 3C).
The proportion of prevalent infections strictly attrib-
uted to PAT exposure was increasing and reached a peak
of 19.9% in 1972, but declined thereafter to 7.4% by
2000 and 5.5% by 2018 (Figure 4A). The cumulative num-
ber of individuals who have ever been infected strictly due
to PAT exposure was 963 900 by 2018, but the number of
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them who were alive was 850 200 in 1980, 642 000 in
2000 and only 389 800 in 2018 (Table 2).
The proportion of new (incident) HCV infections
strictly attributed to PAT exposure peaked in 1965 at
21.4%, declined thereafter and eventually vanished with
the end of PAT campaigns in the early 1980s (Figure 4B).
In 2018, all HCV infections attributed to PAT exposure
were among those >35 years of age (Figure 4C). Notably,
the majority of them, totalling 200 280, were among those
>60 years of age—highlighting the advanced ageing of the
cohort that acquired HCV during PAT campaigns.
The multivariable uncertainty analysis supported the
validity of our results and findings for the role of PAT cam-
paigns in the HCV epidemic (Table 2, Figure 4 and
Supplementary Figure 6, available as Supplementary data
at IJE online). Even with large variations in input parame-
ters, the role of PAT exposure remained qualitatively
invariable.
Supplementary Figures 7 and 8, available as
Supplementary data at IJE online, show the results of the
sensitivity analyses for the role of PAT campaigns in the
HCV epidemic. The analyses affirmed our conclusion that
PAT exposure explains only a minority of HCV infections
in Egypt.
Discussion
Egypt has endured an HCV epidemic of historic propor-
tions,5–8 possibly representing the world’s largest iatro-
genic transmission of blood-borne pathogens known to
date.5 Using an analytical approach anchored on extensive
quality data for HCV and PAT exposure, we aimed to
characterize the historical evolution of this epidemic and
to delineate the role of PAT campaigns. We found that
PAT exposure played an important role in transmission at
the time of the campaigns, between the 1950s and early
Figure 1 Historical trend of HCV antibody (Ab) prevalence in Egypt. (A) Estimated HCV Ab prevalence in the total population between 1950 and 2018.
(B) Estimated HCV Ab prevalence in children (0–14 years), adults (15–59 years) and older adults (>60 years) between 1950 and 2018.
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1980s. However, cumulatively up to the present, PAT ex-
posure has explained only 5.9% of the cumulative number
of 16.4 million infections that have occurred in Egypt since
1950 (Table 2). Notably, among those who are HCV Ab-
positive today, only 5.5% were infected through PAT ex-
posure, the majority of whom are already >60 years of
age. These findings demonstrate that, despite the role of
PAT, the vast majority of infections have been acquired
through other modes of transmission, explaining the ob-
served weak spatial association between HCV prevalence
and PAT exposure seen in the spatial scan statistical
analyses.7
Strikingly, even during the peak of the PAT campaigns,
<25% of the incidence could be explained by PAT expo-
sure (Figure 4B). Even for those exposed to PAT in earlier
times but alive after the year 2000, most infections were
acquired through other modes of transmission, sometimes
during the several decades of their lifetime. These findings,
following multiple studies implicating healthcare expo-
sures (other than PAT) in HCV acquisition,6,8 demonstrate
that PAT campaigns were not strictly the cause of the epi-
demic, as much as a ‘symptom’ of the less-than-optimal
quality of healthcare and limited awareness of blood-borne
infection control, at the time of the campaigns and in sub-
sequent decades. The reuse of syringes and lax sterilization
practices may have been common well beyond PAT cam-
paigns and up to recent times.6,8,44
With all the evidence on HCV epidemiology6–8 and in-
fection control44 being Egyptian in context, it seems most
consistent and logical to hypothesize that the cause of the
epidemic is the mass expansion of healthcare services and
infrastructure in Egypt, which accelerated during the PAT
campaigns and subsequent decades, but whose implemen-
tation did not adequately adhere to the best practices of
infection control. Much of the transmission may have oc-
curred through formal and informal healthcare proce-
dures,6,8 resulting in a series of clustered micro-epidemics.
These micro-epidemics represent large and small out-
breaks of different intensities, as opposed to one large
epidemic.7
Figure 2 Historical trend of HCV incidence in Egypt. (A) Estimated HCV-incidence rate in the total population of Egypt between 1950 and 2018.
(B) Estimated annual number of new HCV infections in the total population of Egypt between 1950 and 2018.
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Demography is perhaps the most underappreciated fac-
tor in understanding the epidemic. Egypt has been witness-
ing a rapid growth in population size over the decades,
with the population increasing 3-fold since 1965,40 coin-
ciding with the height of the PAT campaigns and associ-
ated HCV incidence. The mortality rate was also high at
this time, but has declined steadily in recent decades, lead-
ing to major increases in life expectancy.40 Accordingly,
most of those who acquired HCV through PAT exposure
are no longer alive today (Table 2). Even though the HCV-
incidence rate declined substantially after the peak of the
PAT era (Figure 2A), it remained considerable at a time
when the population was increasing rapidly (along with its
life expectancy), leading to a large number of incident
infections and subsequently prevalent infections
(Figure 2B). Most infected individuals alive today acquired
their infection after the PAT campaigns were phased out in
the early 1980s. This further demonstrates that PAT
Figure 3 Temporal evolution of PAT exposure and the HCV epidemic in Egypt. (A) Projected population proportion of PAT exposure in the total popu-
lation between 1950 and 2018. (B) Projected HCV antibody (Ab) prevalence in those exposed to PAT between 1950 and 2018. (C) Projected proportion
of individuals exposed to PAT among those who were HCV Ab-positive between 1950 and 2018.
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exposure is just one driver of incidence, but most incident
infections appear to be related to broader healthcare
practices.
The modelled epidemic history highlights several nota-
ble findings. Whereas the HCV-incidence rate (i.e. the
likelihood of infection for a given person) was highest dur-
ing the peak of the PAT era in the 1960s (Figure 2A), the
incidence (annual number of new infections) was the high-
est more than two decades later in around 1990
(Figure 2B)—the decline in the incidence rate following the
Figure 4 Role of PAT exposure in the Egypt HCV epidemic. (A) Estimated proportion of the prevalent HCV infections that were strictly attributed to
PAT exposure between 1950 and 2018. (B) Estimated proportion of the new (incident) HCV infections that were strictly attributed to PAT exposure be-
tween 1950 and 2018. (C) Estimated age distribution of the number of living individuals who had acquired HCV strictly through PAT exposure by
2018.
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PAT era was more than compensated for by the rapid pop-
ulation growth from the 1970s to the 1990s. Since 1993,
both the incidence rate and the incidence have been declin-
ing very rapidly (Figure 2), likely due to blood screening,
improved injection safety and infection control following
the identification of the virus in 198945,46 and discovery of
the epidemic in Egypt in the early 1990s.47,48
Another notable finding is that there are two ‘cohort
effects’ in the Egypt epidemic, best seen in the two
incidence peaks in Figure 2B. The first cohort is the
well-known and characterized ‘PAT-era cohort’,5
whereas the second is that of the rapid population
growth and high-incidence era between the 1970s and
the 1990s. This latter cohort, labelled here as the ‘high-
incidence cohort’, constitutes the most infected people
alive today in Egypt.
There are limitations in this study. A sophisticated dy-
namical modelling approach was used to capture transmis-
sion dynamics that was refined and perfected over a series
of applications,9,38,49 although model projections are con-
tingent on the quality and representativeness of the input
data. PAT-exposure data were extracted from the EDHS
databases.10,34 Whereas these surveys are of high quality
and are nationally representative, PAT exposure was mea-
sured through self-reporting and thus could be prone to
reporting or recall bias. Nevertheless, the conducted sensi-
tivity analysis affirmed our findings even in the presence of
a large reporting bias in the PAT-exposure data
(Supplementary Figure 7, available as Supplementary data
at IJE online).
Whereas a large database of systematically extracted
HCV Ab-prevalence data was used to fit the model (practi-
cally every available measure in the literature6), fitting the
model to the era before the discovery of the epidemic
hinged on the availability of age-specific prevalence data to
capture historical exposure over time. Therefore, the un-
certainty in the estimates increases as the projections go
further back in time, with less age-cohort data becoming
available. Despite this wide uncertainty in the earlier years,
the uncertainty analysis supported our predictions that
PAT exposure contributed to only a minority of infections
(Supplementary Figure 6, available as Supplementary data
at IJE online).
Disease-related mortality was not incorporated in the
model, but the relative risk of mortality with infection is
relatively too small to appreciably affect the projec-
tions.9,43,50 Even if it did, it would have further lowered
the estimates for the role of PAT exposure in the epidemic.
Indeed, this was the case, as demonstrated by the con-
ducted sensitivity analysis incorporating HCV-disease-
related mortality (Supplementary Figure 8, available as
Supplementary data at IJE online).
Despite these limitations, a major strength of this study
is that it provided a comprehensive characterization of the
epidemic’s historical evolution that is anchored on an ex-
tensive and quality foundation of epidemiologic evidence
and incorporated the intricate demography of the Egyptian
population. Even by factoring in the uncertainty in the
modelled projections (Figure 4), the conclusions on the
role of PAT exposure were invariable.
To sum up, even though PAT campaigns played an im-
portant role in HCV transmission in Egypt, they explain
only 6% of the infections that occurred since 1950. Most
infections have been acquired through other modes of
transmission, sometime over the past few decades. PAT
campaigns were not the main cause of the epidemic—the
ultimate driver of the epidemic is presumably the mass ex-
pansion of healthcare services and infrastructure that ac-
celerated during the PAT campaigns and subsequent
decades, but whose implementation did not adequately ad-
here to the best practices of infection control. Whereas
broad healthcare practices may have driven the epidemic,
demographic trends amplified it, leading to an immense ex-
pansion and a high-incidence-cohort effect for those who
acquired the infection between the 1970s and the 1990s.
Despite this historical adversity, the epidemic has been rap-
idly diminishing since the mid-1990s, with curtailed inci-
dence at present.
Supplementary Data
Supplementary data are available at IJE online.
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